The invention relates to compounds of Formula (I) and methods for their preparation. Also described are pharmaceutical compositions comprising a compound of Formula (I) and their use in the treatment or prevention of conditions associated with mitochondrial dysfunction. Formula (I) ##STR00001##

The present invention relates to novel lignin-derived compounds and compositions comprising the same and their use as redox flow battery electrolytes. The invention further provides a method for preparing said compounds and compositions as well as a redox flow battery comprising said compounds and compositions. Additionally, an assembly for carrying out the inventive method is provided.

The present invention relates to novel lignin-derived compounds and compositions comprising the same and their use as redox flow battery electrolytes. The invention further provides a method for preparing said compounds and compositions as well as a redox flow battery comprising said compounds and compositions. Additionally, an assembly for carrying out the inventive method is provided.

The present application discloses methods for the efficient preparation of high purity compounds of the Formula I, and their methods of use.

##STR00001##

The present application discloses methods for the efficient preparation of high purity compounds of the Formula I, and their methods of use.

##STR00001##

The present application discloses methods for the efficient preparation of high purity compounds of the Formula I, and their methods of use. ##STR00001## Also disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of a menaquinol compound as disclosed above, or a mixture thereof, and a pharmaceutically acceptable excipient, wherein the composition is effective for the treatment of a condition associated with vitamin K selected from for the treatment of osteoporosis and arteriosclerosis.

The present application discloses methods for the efficient preparation of high purity compounds of the Formula I, and their methods of use. ##STR00001## Also disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of a menaquinol compound as disclosed above, or a mixture thereof, and a pharmaceutically acceptable excipient, wherein the composition is effective for the treatment of a condition associated with vitamin K selected from for the treatment of osteoporosis and arteriosclerosis.

The invention relates to compounds of Formula (I) and methods for their preparation. Also described are pharmaceutical compositions comprising a compound of Formula (I) and their use in the treatment or prevention of conditions associated with mitochondrial dysfunction. Formula (I)

##STR00001##

The invention relates to compounds of Formula (I) and methods for their preparation. Also described are pharmaceutical compositions comprising a compound of Formula (I) and their use in the treatment or prevention of conditions associated with mitochondrial dysfunction. Formula (I)

##STR00001##

In a production method of the present disclosure, a 1,1-binaphthyl precursor derivative, an organic acid, and an iodinating or brominating agent are mixed. The 1,1-binaphthyl precursor derivative has a 1,1-binaphthyl skeleton and has an electron-donating group at the 2-position of the 1,1-binaphthyl skeleton and at the 2-position of the 1,1-binaphthyl skeleton, and the electron-donating group contains an oxygen atom directly bonded to the skeleton. With the production method of the present disclosure, a 1,1-binaphthyl derivative having a substituent introduced at the 8-position and/or 8-position of the 1,1-binaphthyl skeleton can be obtained. The 1,1-binaphthyl derivative obtained by the production method of the present disclosure can be a compound further having a substituent introduced at at least one position selected from the 4-position, 4-position, 5-position, 5-position, 6-position, and 6-position of the 1,1-binaphthyl skeleton.